Elias Said

Title: The Innovative Contributions of Elias Said

Introduction

Elias Said is a notable inventor based in Villejuif, France. He has made significant contributions to the field of immunology, particularly in the development of synthetic peptide vaccines for HIV. With a total of 2 patents, his work has the potential to impact the future of HIV treatment and prevention.

Latest Patents

Elias Said's latest patents focus on synthetic peptide vaccines for HIV. These patents detail the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV. The invention includes peptides such as CBD-1, CBD-2, CBM-1/TH-1, CBM-1/TH-2, CBM-2/TH-1, CBM-2/TH-2, and C-20 peptides. These peptides are antigenic and elicit a protective immune response against HIV infection. The patents also encompass compositions, pharmaceutical formulations, and vaccines that include these antigenic peptides, as well as neutralizing antibodies that inhibit the infection of primary CD4+ T lymphocytes by various HIV isolates. Additionally, methods for the diagnosis of HIV are disclosed in these patents.

Career Highlights

Elias Said has worked with prestigious institutions such as Institut Pasteur and the Centre National de La Recherche Scientifique. His experience in these organizations has contributed to his expertise in immunology and vaccine development.

Collaborations

Elias has collaborated with notable individuals in his field, including Ara G Hovanessian and Jean-Paul Briand. These collaborations have likely enhanced his research and innovation efforts.

Conclusion

Elias Said's work in developing synthetic peptide vaccines for HIV represents a significant advancement in the fight against this virus. His contributions to immunology and collaboration with esteemed institutions and individuals highlight his dedication to improving public health.